Investigation of serum biomarkers for neuropathic pain in neuromyelitis optica spectrum disorder: a preliminary study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: We aimed to investigate candidates for serological biomarkers of neuropathic pain in individuals with neuromyelitis optica spectrum disorder (NMOSD). Methods: We analyzed 38 sera samples from 38 participants with NMOSD in National Cancer Center. Neuropathic pain was evaluated using the painDETECT questionnaire. Pain with neuropathic components (painDETECT score ≥ 13) was observed in 22 participants, among whom 17 had definite neuropathic pain (painDETECT score ≥ 19). The remaining 16 participants had non-neuropathic pain (painDETECT score < 13). Serum glial fibrillary acidic protein (GFAP) levels were assessed using a single-molecule array assay. Several cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-10, and IL-17A, were measured by a multiplex bead-based immunoassay. Results: In comparison of NMOSD participants with neuropathic pain components (or definite neuropathic pain) and those with non-neuropathic pain, the absolute values of serum GFAP, TNF-α, IL-6, and IL-10 levels were higher in participants with neuropathic pain components (or definite neuropathic pain), but these findings did not reach statistical significance. Conclusions: Further larger-scale investigations to find reliable serological biomarkers for neuropathic pain in NMOSD are warranted.
Abstract
Background: We aimed to investigate candidates for serological biomarkers of neuropathic pain in individuals with neuromyelitis optica spectrum disorder (NMOSD). Methods: We analyzed 38 sera samples from 38 participants with NMOSD in National Cancer Center. Neuropathic pain was evaluated using the painDETECT questionnaire. Pain with neuropathic components (painDETECT score ≥ 13) was observed in 22 participants, among whom 17 had definite neuropathic pain (painDETECT score ≥ 19). The remaining 16 participants had non-neuropathic pain (painDETECT score < 13). Serum glial fibrillary acidic protein (GFAP) levels were assessed using a single-molecule array assay. Several cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-10, and IL-17A, were measured by a multiplex bead-based immunoassay. Results: In comparison of NMOSD participants with neuropathic pain components (or definite neuropathic pain) and those with non-neuropathic pain, the absolute values of serum GFAP, TNF-α, IL-6, and IL-10 levels were higher in participants with neuropathic pain components (or definite neuropathic pain), but these findings did not reach statistical significance. Conclusions: Further larger-scale investigations to find reliable serological biomarkers for neuropathic pain in NMOSD are warranted.
참고문헌 (23)
- Bradl M, "Pain in neuromyelitis optica--prevalence, pathogenesis and therapy", Nat Rev Neurol, 10, pp.529~536 (2014)
- 현재원, "Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis", Journal of Clinical Neurology, 16(1), pp.124~130 (2020), 대한신경과학회
- Watanabe M, "Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD", Neurology, 93, pp.e1299~e1311 (2019)
- Uzawa A, "Cytokine and chemokine profiles in neuromyelitis optica : significance of interleukin-6", Mult Scler, 16, pp.1443~1452 (2010)
- Sung JK, "Korean version of the painDETECT questionnaire : a study for cultural adaptation and validation", Pain Pract, 17, pp.494~504 (2017)
- Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
- 김예슬, "Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria", Journal of Clinical Neurology, 13(2), pp.175~180 (2017), 대한신경과학회[DOI]
- Freynhagen R, "The painDETECT project-far more than a screening tool on neuropathic pain", Curr Med Res Opin, 32, pp.1033~1057 (2016)
- Lennon VA, "A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis", Lancet, 364, pp.2106~2112 (2004)
- Hung AL, "Targeting cytokines for treatment of neuropathic pain", Scand J Pain, 17, pp.287~293 (2017)
- Wei XH, "Peri-sciatic administration of recombinant rat TNF-alpha induces mechanical allodynia via upregulation of TNF-alpha in dorsal root ganglia and in spinal dorsal horn : the role of NF-kappa B pathway", Exp Neurol, 205, pp.471~484 (2007)
- Zanella JM, "Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model", Spine(Phila Pa 1976), 33, pp.227~234 (2008)
- Wang K, "A cohort study comparing the serum levels of pro-or anti-inflammatory cytokines in patients with lumbar radicular pain and healthy subjects", Eur Spine J, 25, pp.1428~1434 (2016)
- Bo Zu, "Serum Levels of the Inflammatory Cytokines in Patients with Lumbar Radicular Pain Due to Disc Herniation", Asian Spine Journal, 10(5), pp.843~849 (2016), 대한척추외과학회
- "Information on Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi)" (2021)[URL]
- Kemanetzoglou E, "CNS demyelination with TNF-αblockers", Curr Neurol Neurosci Rep, 17, pp.36~ (2017)
- Ramer MS, "Spinal nerve lesion-induced mechanoallodynia and adrenergic sprouting in sensory ganglia are attenuated in interleukin-6 knockout mice", Pain, 78, pp.115~121 (1998)
- Guptarak J, "Inhibition of IL-6 signaling : a novel therapeutic approach to treating spinal cord injury pain", Pain, 154, pp.1115~1128 (2013)
- Araki M, "Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study", Neurology, 82, pp.1302~1306 (2014)
- Kim CF, "Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice", J Pain, 12, pp.370~383 (2011)
- Day YJ, "Lack of interleukin-17 leads to a modulated micro-environment and amelioration of mechanical hypersensitivity after peripheral nerve injury in mice", Pain, 155, pp.1293~1302 (2014)
- Shao Q, "IL-10 and IL-1β mediate neuropathic-pain like behavior in the ventrolateral orbital cortex", Neurochem Res, 40, pp.733~739 (2015)